세계의 인간면역결핍바이러스 치료제 시장 : 부문별 예측(2025-2030년)

The Human Immunodeficiency Virus Therapeutics Market was valued at USD 19.34 billion in 2023, expected to reach USD 20.28 billion in 2024, and is projected to grow at a CAGR of 4.63%, to USD 26.55 billion by 2030.

Human Immunodeficiency Virus (HIV) Therapeutics encompass a range of treatments designed to manage HIV infection, improve quality of life, and extend patient lifespan. These therapeutics include antiretroviral therapies (ART), integrase inhibitors, and protease inhibitors, among others. The necessity for HIV therapeutics arises from the persistent global burden of the disease, necessitating continued research and development to address virus mutation and resistance issues. These therapies are primarily applied in healthcare settings and serve a diverse end-use demographic, including hospitals, specialty clinics, and direct purchase markets. The HIV therapeutics market is spurred by increased HIV diagnosis rates, advancements in drug development, and government initiatives that enhance accessibility to treatment options. Key growth factors include ongoing pharmaceutical innovations, rising awareness about HIV treatment, and improved healthcare infrastructure, especially in developing regions. Recent opportunities lie in the integration of artificial intelligence in drug discovery and personalized medicine approaches, which can optimize treatment efficacy and patient outcomes. Companies should consider expanding partnerships with biotechnology firms and investing in research focusing on novel drug formulations and delivery mechanisms to tap into these opportunities. However, market growth faces limitations such as high treatment costs, potential side effects, and social stigma associated with HIV, which can hinder patient access to care. Ensuring affordability and addressing these social barriers are crucial challenges. The most promising areas for innovation include the development of long-acting injectable antiretrovirals, once-monthly regimens, and exploring gene-editing technologies like CRISPR for potential curative strategies. The HIV therapeutics market is dynamic, heavily influenced by policy changes, scientific advancements, and epidemiological trends. Businesses should prioritize R&D investments and engage with public health entities to remain competitive and meet shifting market demands effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Immunodeficiency Virus Therapeutics Market

The Human Immunodeficiency Virus Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of HIV infections particularly amongst the youth
  • Rising awareness about infection and availability of efficient treatments
  • Increasing funding and approval of drugs
• Market Restraints
  • High cost of antiretroviral therapies and rising drug resistance
• Market Opportunities
  • Collaborative efforts of government and various NGOs
  • Technological advancements in point-of-care testing for HIV
• Market Challenges
  • Lack of awareness about the mode of transmission

Porter's Five Forces: A Strategic Tool for Navigating the Human Immunodeficiency Virus Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Immunodeficiency Virus Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Immunodeficiency Virus Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Immunodeficiency Virus Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Immunodeficiency Virus Therapeutics Market

A detailed market share analysis in the Human Immunodeficiency Virus Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Immunodeficiency Virus Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Immunodeficiency Virus Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Immunodeficiency Virus Therapeutics Market

A strategic analysis of the Human Immunodeficiency Virus Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Immunodeficiency Virus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., BioNTech SE, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, CytoDyn Inc., Dewpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, ImmunityBio, Inc., Johnson & Johnson Services, Inc., Mylan NV, Pfizer, Inc., Starpharma Holdings Limited, TaiMed Biologics, Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Immunodeficiency Virus Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside-Analog Reverse Transcriptase Inhibitors, and Protease Inhibitors.
• Based on End-User, market is studied across Hospitals & Clinics and Specialty Centers.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of HIV infections particularly amongst the youth
    • 5.1.1.2. Rising awareness about infection and availability of efficient treatments
    • 5.1.1.3. Increasing funding and approval of drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of antiretroviral therapies and rising drug resistance
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative efforts of government and various NGOs
    • 5.1.3.2. Technological advancements in point-of-care testing for HIV
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness about the mode of transmission
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Coreceptor Antagonists
• 6.3. Entry & Fusion Inhibitors
• 6.4. Integrase Inhibitors
• 6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
• 6.6. Nucleoside-Analog Reverse Transcriptase Inhibitors
• 6.7. Protease Inhibitors

7. Human Immunodeficiency Virus Therapeutics Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Specialty Centers

8. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Human Immunodeficiency Virus Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Human Immunodeficiency Virus Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. BioNTech SE
• 3. Boehringer Ingelheim GmbH
• 4. Bristol-Myers Squibb Company
• 5. Cipla Limited
• 6. CytoDyn Inc.
• 7. Dewpoint Therapeutics Inc.
• 8. F. Hoffmann-La Roche Ltd.
• 9. Genentech, Inc.
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline PLC
• 12. ImmunityBio, Inc.
• 13. Johnson & Johnson Services, Inc.
• 14. Mylan NV
• 15. Pfizer, Inc.
• 16. Starpharma Holdings Limited
• 17. TaiMed Biologics, Inc.
• 18. Teva Pharmaceutical Industries Ltd.